Increased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapy

Table 2 Relationship between molecules and treatment outcome

	sIL-2R	p value	PD-L1	p value	pAkt (Ser-473)	p value
	(U/ml)		(pg/ml)		pAkt (Ser-473)
	mean ± S.D		mean ± S.D		mean ± S.D
IFN-alpha group
IFN alone: CR/PR/SD > 24w* (n = 6)	123.9 ± 43.1	0.01	17.3 ± 13.0	0.02	2.67 ± 0.93	0.01
IFN + Sor: CR/PR/SD > 24w* (n = 19)	331.6 ± 207.7		18.6 ± 15.8		3.93 ± 2.09
IFN + Sor: SD < 24w/PD* (n = 22)	567.3 ± 577.6		60.1 ± 98.2		6.42 ± 2.52
Axitinib: CR/PR/SD > 24w* (n = 9)	433.3 ± 205.2		27.2 ± 16.4		5.95 ± 2.85
Axitinib: SD < 24w/PD* (n = 11)	1050.1 ± 710.8		43.8 ± 24.6		7.01 ± 2.57
1st and/or 2nd and/or 3rd therapy*
CR/PR/SD > 24w* (n = 29)	367.1 ± 242.3	0	18.0 ± 12.9	0	3.69 ± 1.97	0
SD < 24w/PD* (n = 18)	784.5 ± 558.4	0	41.6 ± 20.7	0	6.67 ± 2.51	0

CR/PR/SD>24w* : complete, partial, or stable with > 24 weeks response
SD<24w/PD* : stable disease for < 24 weeks or progressive disease
1st and/or 2nd and/or 3rd therapy* : IFN-alpha (1st-line), IFN-alpha + Sorafenib (2nd-line), Axitinib (3rd-line)

ISSN: 1471-2407